Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02334501 · ClinicalTrials.gov registry record · Phase 1
Open-label PK Study to Evaluate Lansoprazole and Neratinib in Healthy Subjects
A Phase 1 study, sponsored by Puma Biotechnology.
- Completed
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT02334501 is a Phase 1 study that has completed, run by Puma Biotechnology. The registered enrollment target is 15 participants.
The verdict
NCT02334501, a Phase 1 study, has completed, sponsored by Puma Biotechnology.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
This is an open label, 2-period, fixed-sequence study in 15 healthy adult subjects under fed conditions. To evaluate the effect of multiple doses of lansoprazole on the absorption and pharmacokinetics (PK) of a single dose of neratinib in healthy subjects.
Interventions
- DRUG Neratinib
- DRUG Lansoprazole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2014-08 |
| Est. Completion | 2014-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02334501
The ClinicalTrials.gov registry entry for NCT02334501 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Puma Biotechnology, which has 28 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Neratinib is the first listed.
NCT02334501 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02334501 about?
NCT02334501 is a clinical study titled "Open-label PK Study to Evaluate Lansoprazole and Neratinib in Healthy Subjects". This is an open label, 2-period, fixed-sequence study in 15 healthy adult subjects under fed conditions. To evaluate the effect of multiple doses of lansoprazole on the absorption and pharmacokinetics (PK) of a single dose of neratinib in healthy subjects.
What is the current status of trial NCT02334501?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2014-08. Estimated completion is 2014-10.
What interventions are being tested in trial NCT02334501?
The interventions under investigation include: Neratinib (DRUG), Lansoprazole (DRUG).
Who is sponsoring clinical trial NCT02334501?
This trial is sponsored by Puma Biotechnology, which has 28 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.